Cytotoxicity mediation of cells evidencing surface expression of CD63
AssigneeArius Research, Inc.
InventorsDavid S. F. Young, Helen P. Findlay, Susan E. Hahn, Luis A. G. da Cruz, Daad Sayegh, Kristian Rogers, Shankar Kumar, Paul Hinton
Life of this patent
Estimating the term…
Abstract
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
Claims5
An isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141205-06 or an antigen binding fragment thereof wherein the monoclonal antibody or antigen binding fragment thereof binds CD63.
The isolated clone deposited with the IDAC as accession number 141205-06.
Dependencies are inferred from the claim text.